Literature DB >> 27531557

Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.

Jing Yi1, Li Lu2, Kilangsungla Yanger3,4, Wenqi Wang5, Bo Hwa Sohn6, Ben Z Stanger3,4,7, Min Zhang8, James F Martin8, Jaffer A Ajani9, Junjie Chen5, Ju-Seog Lee6, Shumei Song9, Randy L Johnson10,11,12.   

Abstract

In the adult liver, the Hippo pathway mammalian STE20-like protein kinases 1 and 2 and large tumor suppressor homologs 1 and 2 (LATS1/2) control activation of the transcriptional coactivators Yes-associated protein (YAP) and WW domain containing transcription regulator 1 (TAZ) in hepatocytes and biliary epithelial cells, thereby regulating liver cell proliferation, differentiation, and malignant transformation. Less is known about the contribution of Hippo signaling to liver development. We used conditional mutagenesis to show that the Hippo signaling pathway kinases LATS1 and LATS2 are redundantly required during mouse liver development to repress YAP and TAZ in both the biliary epithelial and hepatocyte lineages. In the absence of LATS1/2, biliary epithelial cells exhibit excess proliferation while hepatoblasts fail to mature into hepatocytes, defects that result in perinatal lethality. Using an in vitro hepatocyte differentiation assay, we demonstrate that YAP activity decreases and Hippo pathway kinase activities increase upon differentiation. In addition, we show that YAP activation in vitro, resulting from either depletion of its negative regulators LATS1/2 or expression of a mutant form of YAP that is less efficiently phosphorylated by LATS1/2, results in transcriptional suppression of genes that normally accompany hepatocyte maturation. Moreover, we provide evidence that YAP activity is repressed by Hippo pathway activation upon hepatocytic maturation in vitro. Finally, we examine the localization of YAP during fetal liver development and show that higher levels of YAP are found in biliary epithelial cells, while in hepatocytes YAP levels decrease with hepatocyte maturation.
CONCLUSION: Hippo signaling, mediated by the LATS1 and LATS2 kinases, is required to restrict YAP and TAZ activation during both biliary and hepatocyte differentiation. These findings suggest that dynamic regulation of the Hippo signaling pathway plays an important role in differentiation and functional maturation of the liver. (Hepatology 2016;64:1757-1772).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27531557      PMCID: PMC5863546          DOI: 10.1002/hep.28768

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

1.  Cell density-dependent regulation of hepatic development by a gp130-independent pathway.

Authors:  N Kojima; T Kinoshita; A Kamiya; K Nakamura; K Nakashima; T Taga; A Miyajima
Journal:  Biochem Biophys Res Commun       Date:  2000-10-14       Impact factor: 3.575

2.  Inducible differentiation and morphogenesis of bipotential liver cell lines from wild-type mouse embryos.

Authors:  Hélène Strick-Marchand; Mary C Weiss
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

Review 3.  The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease.

Authors:  Xaralabos Varelas
Journal:  Development       Date:  2014-04       Impact factor: 6.868

4.  Hippo pathway activity influences liver cell fate.

Authors:  Dean Yimlamai; Constantina Christodoulou; Giorgio G Galli; Kilangsungla Yanger; Brian Pepe-Mooney; Basanta Gurung; Kriti Shrestha; Patrick Cahan; Ben Z Stanger; Fernando D Camargo
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

5.  Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size.

Authors:  Mei Xin; Yuri Kim; Lillian B Sutherland; Xiaoxia Qi; John McAnally; Robert J Schwartz; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Sci Signal       Date:  2011-10-25       Impact factor: 8.192

6.  Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9.

Authors:  Aline Antoniou; Peggy Raynaud; Sabine Cordi; Yiwei Zong; François Tronche; Ben Z Stanger; Patrick Jacquemin; Christophe E Pierreux; Frederic Clotman; Frederic P Lemaigre
Journal:  Gastroenterology       Date:  2009-02-21       Impact factor: 22.682

7.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

8.  TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function.

Authors:  Jiayi Wang; Joo-Seop Park; Yingying Wei; Mihir Rajurkar; Jennifer L Cotton; Qishi Fan; Brian C Lewis; Hongkai Ji; Junhao Mao
Journal:  Mol Cell       Date:  2013-06-13       Impact factor: 17.970

9.  The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.

Authors:  Nailing Zhang; Haibo Bai; Karen K David; Jixin Dong; Yonggang Zheng; Jing Cai; Marco Giovannini; Pentao Liu; Robert A Anders; Duojia Pan
Journal:  Dev Cell       Date:  2010-07-20       Impact factor: 12.270

10.  A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.

Authors:  Toshiro Moroishi; Hyun Woo Park; Baodong Qin; Qian Chen; Zhipeng Meng; Steven W Plouffe; Koji Taniguchi; Fa-Xing Yu; Michael Karin; Duojia Pan; Kun-Liang Guan
Journal:  Genes Dev       Date:  2015-06-15       Impact factor: 11.361

View more
  40 in total

1.  Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.

Authors:  Joshua M Adams; Kari A Huppert; Eumenia C Castro; Mario F Lopez; Nima Niknejad; Sanjay Subramanian; Neda Zarrin-Khameh; Milton J Finegold; Stacey S Huppert; Hamed Jafar-Nejad
Journal:  Hepatology       Date:  2020-01-24       Impact factor: 17.425

Review 2.  Hippo-YAP signaling in digestive system tumors.

Authors:  Feng Yin; Jixin Dong; Liang-I Kang; Xiuli Liu
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

3.  YAP/TAZ and Hedgehog Coordinate Growth and Patterning in Gastrointestinal Mesenchyme.

Authors:  Jennifer L Cotton; Qi Li; Lifang Ma; Joo-Seop Park; Jiayi Wang; Jianhong Ou; Lihua J Zhu; Y Tony Ip; Randy L Johnson; Junhao Mao
Journal:  Dev Cell       Date:  2017-09-21       Impact factor: 12.270

4.  The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.

Authors:  Wenbo Ma; Chang Han; Jinqiang Zhang; Kyoungsub Song; Weina Chen; Hyunjoo Kwon; Tong Wu
Journal:  Hepatology       Date:  2020-10-09       Impact factor: 17.425

5.  Core Hippo pathway components act as a brake on Yap and Taz in the development and maintenance of the biliary network.

Authors:  Zachary J Brandt; Ashley E Echert; Jonathan R Bostrom; Paula N North; Brian A Link
Journal:  Development       Date:  2020-06-22       Impact factor: 6.868

Review 6.  The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.

Authors:  Noa Furth; Yael Aylon
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

7.  Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway.

Authors:  Juan Mo; Jean-Philippe Brosseau; Zhiguo Chen; Tracey Shipman; Yong Wang; Chung-Ping Liao; Jonathan M Cooper; Robert J Allaway; Sara J C Gosline; Justin Guinney; Thomas J Carroll; Lu Q Le
Journal:  Cancer Discov       Date:  2018-10-22       Impact factor: 39.397

Review 8.  The Hippo Signaling Pathway in Development and Disease.

Authors:  Yonggang Zheng; Duojia Pan
Journal:  Dev Cell       Date:  2019-08-05       Impact factor: 12.270

9.  Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction.

Authors:  Han Han; Ruxi Qi; Jeff Jiajing Zhou; Albert Paul Ta; Bing Yang; Hiroki J Nakaoka; Gayoung Seo; Kun-Liang Guan; Ray Luo; Wenqi Wang
Journal:  Mol Cell       Date:  2018-10-04       Impact factor: 17.970

10.  Lats1/2 Sustain Intestinal Stem Cells and Wnt Activation through TEAD-Dependent and Independent Transcription.

Authors:  Qi Li; Yang Sun; Gopala K Jarugumilli; Shun Liu; Kyvan Dang; Jennifer L Cotton; Jordi Xiol; Pui Yee Chan; Michael DeRan; Lifang Ma; Rui Li; Lihua J Zhu; Joyce H Li; Andrew B Leiter; Y Tony Ip; Fernando D Camargo; Xuelian Luo; Randy L Johnson; Xu Wu; Junhao Mao
Journal:  Cell Stem Cell       Date:  2020-04-06       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.